Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-08-13 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
第三届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 17th meeting of the third board of directors of Inner Mongolia Datang Pharmaceutical Co., Ltd. It includes information about board member nominations, election proposals, amendments to company bylaws, and other board-related decisions. The document references the nomination and election of new board members and the submission of these proposals to the shareholders' meeting. It also mentions the approval of the 2024 semi-annual report proposal but does not contain the report itself. The content is focused on board and management changes and decisions rather than financial results or regulatory filings. Therefore, the document fits best under the category of Board/Management Information (MANG).
2024-08-13 Chinese
关于召开2024年第一次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2024 first extraordinary general meeting of shareholders for Inner Mongolia Datang Pharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items including board and supervisory committee elections, and amendments to company bylaws. It does not contain actual financial data or results but serves as an official announcement for the shareholders to participate in the meeting and vote. The document length is under 5,000 characters and it primarily serves as a meeting notice rather than a report or results announcement. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-08-13 Chinese
独立董事候选人声明与承诺 （伊利红）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for a company's board. It contains detailed personal qualifications, compliance with legal and regulatory requirements, and a formal commitment to fulfill the duties of an independent director. There are no financial statements, earnings data, or report attachments. The content is related to board/management information, specifically about a director candidate's qualifications and declarations. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and does not indicate an announcement of a report publication or regulatory filing, but rather a formal declaration by a board candidate.
2024-08-13 Chinese
关于拟修订《公司章程》公告
Governance Information Classification · 95% confidence The document is an announcement regarding proposed amendments to the company's Articles of Association (公司章程). It details changes in the board size and references relevant laws and regulations. It is not a full report but a regulatory announcement about governance changes. The document is short (1097 characters) and does not contain financial data or detailed management discussion. It is not a report publication announcement since it contains substantive content about governance changes. Therefore, the most appropriate classification is Governance Information (CGR).
2024-08-13 Chinese
独立董事提名人声明与承诺 （武海艳）
Board/Management Information Classification · 95% confidence The document is a nomination statement and commitment declaration for an independent director candidate (武海艳) for the board of 内蒙古大唐药业股份有限公司. It details the qualifications, independence criteria, and legal compliance of the nominee. There is no financial data, no report or results announcement, no voting results, no management changes announcement, and no regulatory certification. The document is a formal announcement related to board/management information, specifically about the nomination of a board member. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification, so it fits best under MANG.
2024-08-13 Chinese
关于参加内蒙古辖区2024年投资者网上集体接待日活动情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor online collective reception day event organized by regulatory and industry bodies. It includes a summary of questions from investors and the company's responses, covering topics such as product lines, communication channels, production plans, and a note about the upcoming half-year report disclosure. The document does not contain actual financial statements or detailed financial analysis but rather serves as a communication and engagement update with investors. The document length is short (1388 characters) and it references the upcoming half-year report to be disclosed later, indicating it is not the report itself. Therefore, this document is best classified as a Regulatory Filing (RNS) as it is a general regulatory announcement and investor communication that does not fit other specific categories.
2024-08-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.